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inhibits delayed-type hypersensitivity skin reactions to bothImmune responsiveness in renal transplant recipients: Myco-
primary and frequently encountered antigens. Histologicalphenolic acid severely depresses humoral immunity in vivo.
studies indicate an effect on ICAM-1 expression, leaving theBackground. Current immunosuppressive drug treatments
influx of CD3pos T cells unaffected. Administration of a 10-dayfor renal transplant recipients result in high one-year graft sur-
course of IgA CD3 mAb does not add profound immunosup-vival rates. Despite adequate suppression of the immune re-
sponse directed to the allograft, the immune system remains pressive effects on the measured parameters. In contrast, ad-
able to cope with many infectious agents. dition of treatment with MMF profoundly decreases both pri-
Methods. To define the influence of distinct immunosup- mary and secondary humoral immune responsiveness in vivo.
pressive treatment protocols, primary and secondary cellular Finally, no effect of the studied immunosuppressive drugs on
and humoral immune responses in groups of renal transplant Th1/Th2 balance in vivo was measured.
recipients were studied: patient treated with prednisolone and
cyclosporine A (P/CsA); with IgA CD3 monoclonal antibody
as a rejection treatment superimposed on prednisolone and cy-
We recently demonstrated that a substantial propor-closporine A (IgA CD3 mAbP/CsA); and with prednisolone,
cyclosporine A and mycophenolate mofetil (P/CsA/MMF). tion of renal transplant recipients who received double
Results. Primary in vitro proliferative responses to the pro- immunosuppressive therapy consisting of prednisolone
tein antigen keyhole limpet hemocyanin (KLH) were not sig- and cyclosporine A mounted readily detectable T helpernificantly disturbed in P/CsA treated patients, or in IgA CD3
cell responses to newly acquired human cytomegalovirusmAbP/CsA and P/CsA/MMF treated patients. In vitro prolif-
(hCMV) [1]. Moreover, both the anti-hCMV antibody re-erative responses to the recall antigen tetanus toxoid (TT) were
similarly unaffected. Antigen-specific antibody responses to sponse and the hCMV-specific CD8 responses rapidly
immunization with KLH and TT were not affected by treat- followed the T helper cell response (Gamadia et al, un-
ment with P/CsA, or by IgA CD3 mAbP/CsA, but were se-
published observations). Recently, we found that pro-verely disturbed in patients treated with P/CsA/MMF. All
tection against hCMV infections in immunosuppressedpatients displayed a profound inhibition of the delayed-type
hypersensitivity skin reactivity to KLH and recall antigens. renal transplant recipients is achieved mainly through in-
Nevertheless, in most patients with P/CsA treatment, T cell creased frequencies of activated, cytotoxic effector cells
infiltrates were observed in skin biopsies from the site of KLH [2]. Thus, immunosuppressive drug treatment that is of-challenge, while expression of intercellular cell adhesion mole-
ten sufficient to protect renal transplant recipients fromcule-1 (ICAM-1) expression in challenged skin was significantly
rejection of the allograft, also allows for effective cellulardecreased in these patients. The balance between T helper 1
and T helper 2 cells was unaffected by immunosuppressive treat- and humoral immune responses against infections.
ments during one year of follow-up. In a previous study, the influence of cyclosporine A
Conclusions. Immunosuppressive drug treatment with P/CsA
monotherapy on primary and secondary cellular and
humoral immune responses was investigated in renal
transplant recipients [3, 4]. Nowadays, the immunosup-Key words: immunosuppression, kidney transplantation, graft survival,
prednisolone, cyclosporine A, mycophenolate mofetil. pressive drug regimen administered to renal transplant
recipients consists of two and more frequently three
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cells [5, 6]. The effects of glucocorticoids on human MMF group. Renal transplant recipients from the P/CsA
group were immunized at three months after trans-T cells are complex and depend, among other things, on
plantation; patients from the IgA CD3 mAbP/CsAthe differentiation state of the T cells [7]. Mycophenolic
group were immunized at three months after the initia-acid (MMF) has been shown to reduce acute rejection
tion of rejection treatment; patients from the P/CsA/episodes in renal transplant recipients [8–10]. Moreover,
MMF group were immunized at least three months afterMMF was shown to reduce the risk of developing chronic
initiation of the triple immunosuppressive drug regimen.allograft nephropathy, independent of the reduced inci-
At that time, no significant difference was found in renaldence of acute cellular rejection [11].
transplant function between the different patient groups.We evaluated the cellular and humoral immune re-
All blood samples were drawn just before intake ofsponses in three groups of renal transplant recipients
immunosuppressive drug medication. Finally, 10 healthywho were under different immunosuppressive protocols.
control volunteers were included into this study (C.I.,In renal transplant recipients and healthy control individ-
median age at entry 47.5; range 38 to 57; female/maleuals, immunization protocols were performed and the
ratio 6/4). All patients and healthy control individualseffects of treatment consisting of prednisolone and cyclo-
consented to the study, and the study was approved bysporine A (P/CsA), IgA CD3 mAb as a rejection treat-
the local medical ethical committee.ment in addition to prednisolone and cyclosporine A
(IgA CD3 mAbP/CsA) as well as prednisolone, cyclo- Reagents
sporine A and mycophenolate mofetil (P/CsA/MMF) on
Keyhole limpet hemocyanin was prepared as de-primary and secondary, cellular and humoral immune
scribed [13]. Tetanus toxoid for intramuscular injectionresponses were assessed in vivo as well as in vitro. In
(containing at least 40 International Units; WHO) wasaddition, after short-term ex vivo stimulation, the fre-
obtained from Pasteur Merieux MSD (Brussels, Bel-quencies of Th1 and Th2 cells in peripheral blood from
gium). For culture experiments, tetanus toxoid from thethese patients were evaluated.
RIVM (Bilthoven, The Netherlands) was used in a final
concentration of 19 limits of flocculation (Lf)/mL.
METHODS
Immunization, blood sampling, skin tests andSubjects
skin biopsies
Twenty-one renal transplant recipients on basic immu-
One milligram of KLH was administered subcutane-
nosuppressive therapy consisting of prednisolone 10 mg ously in the right arm. In the left arm, 1 mL of tetanus
per day orally and cyclosporine A microemulsions (Neo- toxoid was administered in the deltoid muscle. Before
ral) orally in a dosage scheme adjusted to blood trough as well as 14 days after immunization, blood was drawn
levels of about 150 ng/mL (P/CsA-group) were included to analyze proliferation, frequencies of Th1 and Th2 cells
into this study (median age at entry, 43 years old; range and antibody production. Fourteen days after immuniza-
21 to 71 years old; female/male ratio, 10/11). In addition, tion, intracutaneous KLH (100 g) administration was
six renal transplant recipients receiving a 10 day course performed in the gluteal region of the right leg. In addi-
of CD3 directed monoclonal antibody (mAb) of mouse tion, the CMI-multitest (intracutaneous administration
IgA subclass as a rejection treatment for biopsy-proven of tetanus toxoid, Streptococcus, diphtheria, tuberculin,
acute rejection episodes were investigated (IgA CD3 Candida, Trichophyton and Proteus; Pasteur Me´rieux,
mAbP/CsA-group; median age at entry, 47 years old; Lyon, France) was applied at the frontal side of the
range 18 to 53 years old; female/male ratio, 2/4) [12]. antebrachium, according to the manufacturer’s instruc-
IgA CD3 mAb was administered as 5 mg/day IV (bolus tions. Forty-eight hours later, local induration at the skin
injection) preceded by promethazine 50 mg orally. On test area was palpated, the borders of the induration
the first day of IgA CD3 mAb treatment, the patients were marked off and its diameters were measured in
received 500 mg of methyl prednisolone IV prior to IgA two perpendicular directions. Results are expressed as
CD3 mAb administration. Moreover, seven renal trans- either mean diameters of the indurations (KLH) or num-
plant recipients on immunosuppressive drug therapy ber of indurations equal to or larger than 5 mm (CMI
consisting of prednisolone, cyclosporine A, and myco- multitest). In addition, a 4 mm diameter skin biopsy
phenolate mofetil entered this study (P/CsA/MMF- of the KLH-challenge site was performed under local
group; median age at entry, 50 years old; range 30 to 59 anesthesia. Tissue was snap-frozen in liquid nitrogen and
years old; female/male ratio, 1/6). In these patients, MMF stored at 80C.
was given in a dose of 1 gram b.i.d. orally. Time of entry
Proliferative responses of PBMC to KLH andinto the study was the day of transplantation for the
tetanus toxoidP/CsA group, the first day of rejection treatment for the
IgA CD3 mAbP/CsA group, and at least three months Peripheral blood mononuclear cells (PBMC) were
cultured in six replicates as 50,000 PBMC per well inafter initiation of MMF administration for the P/CsA/
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Table 1. KLH-specific immune responses after immunization
with KLH
Proliferative
response to IgG response to
KLH in vitrob KLH in vivoc
Ratioa 1 1 1 1
CI 1 7 8 0 10 10
P/CsA 0 7 7 1 18 19
IgA CD3 mAbP/CsA 2 4 6 0 6 6
P/CsA/MMF 3 4 7 5 2 7
Total 6 22 28 6 36 42
Abbreviations are: CI, healthy control individuals; P/CsA, renal transplant re-
cipients receiving immunosuppressive drug therapy consisting of prednisolone
and cyclosporine A; IgA CD3 mAbP/CsA, renal transplant recipients receiving
a rejection treatment of IgA CD3 monoclonal antibody plus basic immunosup-
pressive drug therapy consisting of prednisolone and cyclosporine A; P/CsA/MMF,
renal transplant recipients receiving immunosuppressive drug treatment con-
sisting of prednisolone, cyclosporine A and mycophenolate mofetil.
a Ratio of values from 14 days after immunization to values from before immu-
nization. The figures represent numbers of subjects within each treatment group,
either with a ratio 1 or a ratio 1
b Chi-square test, not statistically significant
c Chi-square test, P  0.05
Iscove’s modified Dulbecco’s medium (IMDM), supple-
mented with 5% human pooled serum, penicillin and
streptomycin and -mercapto-ethanol in a final volume
of 170 L per well. KLH was added as 38 g/mL (final
concentration), and tetanus toxoid was added as 19
Lf/mL (final concentration). Thirty-seven MBq/mL
[methyl-3H]thymidine (20L/well; Nycomed Amersham
PLC, Buckinghamshire, UK) was added at day 6 to the
KLH- or tetanus toxoid-stimulated cultures. The plates
were incubated for eight hours at 37C and 5% CO2 in a
humidified chamber. DNA was harvested on filter plates
(UniFilterGF/C, Groningen, The Netherlands) using
the Packard Harvester Filtermate 196 (Packard Instru-
ment Company, Downers Grove, IL, USA) and dried.
Subsequently, scintillation fluid (Packard Bioscience,
Groningen, The Netherlands) was added and filter plates
were sealed (Packard Plate Sealer Micromate 496). In-
corporated 3H-thymidine was measured with a liquid scin-Fig. 1. Cellular and humoral immune responses and delayed-type hy-
persensitivity skin reactions to keyhole limpet hemocyanin (KLH). (A) tillation counter (Packard Topcount microplate scintilla-
Ratio of the proliferative response to KLH of values from 14 days after tion counter). Counts per minute were used as the
immunization to values from before immunization (Y-axis, ratio, log
readout for proliferation.scale) in either healthy control individuals (C.I.;; median before 538.8,
range 172 to 1312 cpm; median after 3707, range 384 to 6802 cpm),
renal transplant recipients receiving prednisolone and cyclosporine A Antibody response against KLH and against
(P/CsA; ; median before 291, range 25 to 909 cpm; median after 1096, tetanus toxoid
range 101 to 1991 cpm), renal transplant recipients who had received
a rejection treatment with IgA CD3 monoclonal antibody (mAb) 3 IgG anti-KLH and IgG anti-tetanus toxoid were mea-
months before, plus basic immunosuppressive treatment consisting of sured by enzyme-linked immunosorbent assay (ELISA)
prednisolone and cyclosporine A (IgA CD3 mAbP/CsA; ; median
as described [3, 13].before 165, range 32 to 4103 cpm; median after 598, range 38 to 2597
cpm); or renal transplant recipients receiving the triple immunosuppres-
sive regimen consisting of prednisolone, cyclosporine A and mycophe-
nolate mofetil (P/CsA/MMF; ; median before 382, range 49 to 10786
cpm; median after 500, range 93 to 4633 cpm). (B) Ratio of IgG anti-
KLH production of values from 14 days after immunization to values 1093 to 5534), and P/CsA/MMF (; median before 129, range 45 to 378;
from before immunization (Y-axis, ratio, log scale) in individuals as in median after 191, range 36 to 353). (C ) Mean diameter of induration
panel A: C.I. (; median before 399, range 136 to 6035; median after of the skin area, 48 hours after intracutaneous skin testing with 100 g
1163, range278 to 1,630,000), P/CsA (; median before 464, range203 KLH (Y-axis, millimeters) of the same individuals as in panel A. There
to 2289; median after 763, range 201 to 5082), IgA CD3 mAbP/CsA were no statistically significant differences, P 	 0.055 by the Kruskal-
(; median before 1163, range 288 to 3558; median after 2083, range Wallis test, except for *P  0.05 by the Mann-Whitney test.
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Fig. 2. Reduced intercellular adhesion molecule-1 (ICAM-1) expression in delayed-type hypersensitivity skin of patients treated with prednisolone/
cyclosporine A. CD3 expression in challenged skin, 48 hours after intracutaneous challenge with 100 g KLH from either a representative healthy
control individual (A) or a representative renal transplant recipient receiving prednisolone and cyclosporine A (B). (C and D) ICAM-1 expression
in challenged skin, 48 hours after intracutaneous challenge with 100 g KLH from the same subjects as in panels A and B, respectively.
Flow cytometric determination of Th1 and Th2 forward scatter and sideward scatter. These events were
subsets in peripheral blood further gated based on either positive CD4 or brightly
positive CD8 expression. Within these gated events,Frequencies of interferon-gamma (IFN-
)- or inter-
the percentages of cells expressing either IFN-
 or IL-4leukin 4 (IL-4)-producing T helper cells were determined
were evaluated.according to the method described by Picker et al [14].
Briefly, PBMC were incubated for four hours in the pres-
Immunohistochemical staining of skin biopsiesence of phorbol 12-myristate 13-acetate (PMA; 1 ng/mL
Frozen 6-m tissue sections were harvested onto slides,final concentration; Sigma Aldrich Chemie GmbH, Dei-
fixed in cold acetone for 10 minutes, air dried and storedsenhofen, Germany), ionomycine (1 g/mL final con-
at 20C until use. Sections were stained with eithercentration; Sigma) and brefeldin A (10 g/mL final con-
CD3 (OKT-3 ascites final dilution 1/1000), anti-vascularcentration; Sigma) in IMDM, containing 10% human
cell adhesion molecule-1 [VCAM-1; clone BBIG-V1pooled serum,  mercapto-ethanol and antibiotics, at
(4B2); 0.4 g/mL final concentration; R&D Systems,37C, in a humidified chamber.
Wiesbaden, Germany], anti-E-selectin [clone BBIG-E4Cells were transferred to FACS tubes, surface stained
(5D11); 4 g/mL final concentration; R&D Systems],with CD4-APC (BD) and CD8-PerCP, fixed in 2 mL
anti-CLA (HECA-452), and anti-intercellular cell adhe-per tube FACS lysing solution (BD), permeabilized in
sion molecule-1 [ICAM-1; clone BBIG-I1(11C81) 0.40.5 mL per tube FACS permeabilizing solution (BD)
g/mL final concentration; R&D Systems] according to afollowed by intracellular staining with anti IFN-
-FITC
previously described protocol [15]. Infiltration of CD3pos(BD) or anti IL-4-PE (BD). To control for cellular stimu-
cells and the expression of E-selectin, ICAM-1 andlation, intracellular CD69 expression was analyzed. Flow
VCAM-1 were scored semiquantitatively as describedcytometric analyses were performed on a FACS Cali-
bur flow cytometer. Lymphocytes were gated based on [16, 17]. CLA positive cells (that is, cells binding the
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HECA-452 antibody) were scored as a percentage of
mononuclear cells.
Statistical analysis
Between-group differences of continuous variables
were analyzed using Kruskal-Wallis test and Mann-Whit-
ney test. Within group analyses of continuous variables
were analyzed using the Wilcoxon’s signed rank test.
Chi-square testing of frequencies was performed. Tests
were performed using SPSS 8.0.2. software program
(SPSS, Inc., Chicago, IL, USA).
RESULTS
In vitro proliferative responses to KLH
after in vivo immunization are relatively intact in
immunosuppressed renal transplant recipients
Since most subjects are considered immunologically
“naive” for KLH, this was used as a model antigen for
the study of primary immune responses toward protein
antigens. Proliferative responses to KLH were evaluated
before and 14 days after subcutaneous immunization
with 1 mg of KLH. In healthy individuals, the median
ratio of these proliferative responses (that is, counts/min
14 days after immunization divided by counts/min before
immunization) was 5.1 (range 0.6 to 20.3; Fig. 1A). In
renal transplant recipients, the ratio of the in vitro prolif-
erative response to KLH was not statistically different
from the healthy control individuals (P/CsA group, me-
dian 2.7, range 1.7 to 8.1; IgA CD3 mAbP/CsA group,
median 1.6, range 0.2 to 18.1; P/CsA/MMF group, me-
dian 1.3, range 0.4 to 4.4). The number of subjects who
responded to KLH immunization with a ratio of their
proliferative response higher than 1 was calculated (Ta-
ble 1). Although not statistically significant, the number
of subjects with a ratio higher than 1, as well as the
magnitude of the T helper cell response tended to be
hampered by addition to the P/CsA treatment of IgA
CD3 mAb or of MMF. We conclude that, on average,
T helper cell responses to KLH can be induced by immu-
nization to KLH in renal transplant recipients.
MMF addition to P/CsA drug therapy abrogates IgG
anti-KLH production in most subjects
IgG anti-KLH responses were analyzed before and
14 days after immunization with 1 mg KLH. Healthy
Fig. 2. (Continued). Frequency distributions of the semiquantitative individuals demonstrated a median 2.4-fold rise in IgG
score after immunohistochemical staining of KLH challenged skin biop-
anti-KLH antibody concentration (range 1.1 to 270.0;sies with CD3 (E ), anti-ICAM-1 (F ) or anti-E-selectin (G ) in skin
biopsies at 48 hours after KLH challenge from either healthy control Fig. 1B). In renal transplant recipients receiving predni-
individuals (C.I., ) or renal transplant recipients receiving predniso- solone and cyclosporine A, the ratio of IgG anti-KLH
lone and cyclosporine A (P/CsA, ). (H ) Frequencies of mononuclear
production was not affected (median ratio 2.0; range 0.9cells expressing the cutaneous lymphocyte-associated antigen (CLA)
as detected by the HECA-452 antibody (Y-axis) in either healthy control to 12.4). In addition, rejection treatment with the CD3
individuals () or renal transplant recipients receiving P/CsA (). directed mAb did not affect IgG anti-KLH production
There were no statistically significant differences in panels E to G by
(median ratio 2.0, range 1.5 to 6.0). In contrast, in patientsthe 2 test, and in panel H by the Mann-Whitney test; P  0.05 in
panel F. receiving triple immunosuppressive therapy (P/CsA/
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MMF), no B cell response was observed in five out of ity of PBMC in response to immunization did not differ
seven patients (median ratio 0.9; range 0.6 to 2.1; Table 1). among the healthy individuals and the renal transplant
From these data, it may be inferred that the addition of recipients in three treatment groups. Median ratios of
MMF abrogates B cell responses toward a new protein the proliferative responses were 2.9 (range 0.5 to 85.6)
antigen upon in vivo immunization, despite the presence in the healthy control individuals, 3.9 (range 2.3 to 62.3)
of residual KLH-specific T helper cell responses. in the P/CsA group, 2.6 (range 0.2 to 13.3) in the IgA
CD3 mAbP/CsA group, and 1.9 (range 0.8 to 8.5) in
Delayed-type hypersensitivity reaction to KLH is the P/CsA/MMF groups (Fig. 3A). Importantly, after
markedly inhibited under systemic treatment with immunization, the majority of the patients from the IgA
P/CsA and P/CsA/MMF CD3 mAbP/CsA and P/CsA/MMF groups demonstrated
Fourteen days after primary immunization with KLH, an enhanced proliferative response to tetanus toxoid
skin reactions to intracutaneous re-challenge with 100g (Table 2).
of KLH were performed. Forty-eight hours thereafter,
IgG anti-tetanus toxoid production cannot beerythema and induration at the injection site were
scored. Figure 1C demonstrates that vigorous skin reac- boosted by immunization under systemic
tions were observed in all tested healthy control individu- treatment with P/CsA/MMF
als. In contrast, none of the renal transplant recipients In most healthy control individuals, tetanus toxoid-
receiving IgA CD3 mAb rejection treatment in addition specific IgG antibodies could be induced by the immuni-
to P/CsA, and only two of the patients from the P/CsA zation protocol (median anti-TT ratio 8.7; range 1.0 to
and P/CsA/MMF groups had indurations to intracuta- 67.7). In renal transplant recipients from both the P/CsA
neous KLH re-challenge (Fig. 1C). and the IgA CD3 mAbP/CsA groups, IgG anti-tetanus
toxoid antibodies also were induced after immunizationSystemic immunosuppression with P/CsA reduces
with median ratios of 7.0 (range 1.1 to 56.2) and 2.8ICAM-1 expression in skin during delayed-type
(range 1.5 to 9.3), respectively (Fig. 3B). In contrast, inhypersensitivity reactions to KLH, while E-selectin
the renal transplant recipients treated with triple immu-expression is not affected
nosuppressants, an antibody response to tetanus toxoid
The observation of profoundly reduced skin reactions was completely absent in four out of six patients treated
in the presence of residual proliferative T helper cell (Table 2). In the other two patients from this treatment
responses to the same antigens prompted us to investi- group, the IgG anti-tetanus toxoid response was very
gate the influx of T cells into the skin test site. In most
small (complete P/CsA/MMF group, median ratio 0.94;
immunosuppressed individuals, perivascular infiltrates
range 0.7 to 1.3).were observed in the dermis in response to the vaccina-
tion (Fig. 2B). Compared to healthy individuals, CD3 Systemic immunosuppression with P/CsA
expression in the challenged skin area from renal trans- based medication reduced the skin reactions
plant recipients was not significantly depressed (Fig. 2 to recall antigens
A, B, and E). Expression of E-selectin on endothelium
To test whether the memory T cells that have beenof challenged skin was similar in healthy individuals and
generated in the absence of immunosuppression are alsorenal transplant recipients (Fig. 2G), as well as the fre-
defective in inducing delayed-type hypersensitivity reac-quency of mononuclear cells expressing the E-selectin
tions, intracutaneous administration were performed withligand CLA. In contrast, in comparison with healthy in-
tetanus toxoid and a panel of six additional antigens:dividuals, renal transplant recipients expressed lower
Proteus, Trichophyton, Candida, Streptococcus, tubercu-levels of ICAM-1 in challenged skin (Fig. 2 C, D and F).
lin and diphtheria. Figure 3C displays the frequency dis-No effect of any of the immunosuppressive drug treat-
tributions of the number of significant skin reactions to anyments on VCAM-1 expression was observed (not shown).
of these antigens in healthy control individuals and in
Proliferative responses to tetanus toxoid the three groups of renal transplant recipients. The num-
are relatively intact in immunosuppressed ber of positive skin reactions was different among the
renal transplant recipients groups. Since the different groups of immunosuppressed
individuals had very similar low responses, the CMI multi-In addition to KLH vaccination, all subjects were si-
test data from these groups of renal transplant recipientsmultaneously immunized with tetanus toxoid intramus-
were pooled. Compared to healthy control individuals,cularly. Proliferative responses to tetanus toxoid were
the relative risk for these renal transplant recipients formeasured before and 14 days after immunization and are
scoring no positive skin reactions as opposed to 1 orpresented as a ratio of the proliferative response after
more positive skin reactions was calculated as 3.0 (95%immunization to the proliferative response before immu-
nization. The tetanus toxoid-induced proliferative capac- Confidence interval, 1.5 to 6.1).
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Fig. 3. Cellular and humoral immune responses
to tetanus toxoid and delayed type hypersensi-
tivity skin reactions to recall antigens. (A) Ra-
tio of the proliferative response to tetanus tox-
oid (TT) of values from 14 days after im-
munization to values from before immuniza-
tion (Y-axis, ratio, log scale) in healthy control
individuals (C.I.,; median before 1145, range
193 to 6398 cpm; median after 7901, range
152 to 16,510 cpm), renal transplant recipients
receiving P/CsA (; median before 856, range
21 to 5288 cpm; median after 3481, range 611
to 24,612 cpm), renal transplant recipients
who had received a rejection treatment of IgA
CD3 monoclonal antibody 3 months before,
plus basic immunosuppressive treatment con-
sisting of P/CsA (IgA CD3 mAbP/CsA; ;
median before 1044, range 103 to 121,891 cpm;
median after 2549, range 235 to 14,236 cpm)
and renal transplant recipients receiving “tri-
ple” immunosuppressive regimen consisting
of P/CsA/MMF (; median before 880, range
35 to 31,456 cpm; median after 1867, range 73
to 39,350 cpm). (B) Ratio of IgG anti-tetanus
toxoid (TT) production of values from 14 days
after immunization to values from before im-
munization. (Y-axis, ratio, log scale) in the
same subjects as in panel A: C.I. (; median
before 962, range 64 to 8828; median after
9048, range 2090 to 16,779), P/CsA (; median
before 295, range 14 to 13,827; median after
5851, range 83 to 17,735), IgA CD3 mAb
P/CsA (; median before 215, range 39 to
5341, median after 1991, range 73 to 9069), and
P/CsA/MMF (; median before 1356, range
1158 to 4313; median after 1404, range 837
to 4653). (C ) Skin test to the recall antigens
showing the frequency distributions of the
number of positive indurations 48 hours after
intracutaneous challenge with 7 different pro-
tein antigens (5 mm mean diameter of indu-
ration, X-axis) versus the number of subjects
(Y-axis) in healthy control individuals and
three groups of immunosuppressed individu-
als as in panel A.
Long-term systemic immunosuppression with P/CsA
does not affect the ex vivo IFN- or IL-4 production
profiles of T cells from peripheral blood
Delayed-type hypersensitivity reactions are generally
considered to be T helper 1 type cell-mediated immune
Table 2. Tetanus toxoid-specific immune responses after reactions. Moreover, T helper 1 cells are more likely toimmunization with tetanus toxoid
enter inflamed skin [18]. Therefore, we examined whether
Proliferative immunosuppressive regimens influence the Th1/Th2 bal-
response to IgG response to
ance in humans. In both healthy control individuals andtetanus toxoid tetanus toxoid
in vitrob in vivoc renal transplant recipients, some variation in the frequen-
cies of IFN-
– and IL-4–producing T helper cells wasRatioa 1 1 1 1
CI 1 7 8 1 9 10 found. However, these changes were not statistically sig-
P/CsA 0 7 7 0 16 16 nificant during the one year follow-up (Fig. 4 A, B). More-
IgA CD3 mAbP/CsA 1 5 6 0 5 5
over, no effect on the ratio of IFN-
–producing to IL-4–P/CsA/MMF 1 6 7 4 2 6
producing cells was observed in these patients (not shown.)
Total 3 25 28 5 32 37
Abbreviations are in Table 1.
a Ratio of values from 14 days after immunization to values from before DISCUSSIONimmunization. The figures represent numbers of subjects within each treatment
group, either with a ratio 1 or a ratio 1 Although much is known on the effects of immunosup-b Chi-square test, not statistically significant
c Chi-square test, P  0.05 pressive drugs on human immune reactivity in vivo and
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Fig. 4. Long-term systemic immunosuppres-
sion with prednisolone/cyclosporine A does
not affect the ex vivo IFN- or IL-4 produc-
tion profiles of T cells from peripheral blood.
(A) Frequencies of IFN-
 producing cells
within peripheral blood CD4pos T cells (Y-axis,
% of CD4pos T cells) versus time after entry
into the study (X-axis, months). Symbols are:
() healthy control individuals (CI); () renal
transplant recipients receiving P/CsA; () re-
nal transplant recipients receiving a rejection
treatment of IgA CD3 mAb  immunosup-
pression treatment of P/CsA. The horizontal
bar in the graph of IgA CD3 mAb
P/CsA represents the time of the rejection
treatment with IgA mouse anti-human CD3.
Time of entry into the study is the day of
transplantation for the P/CsA group and the
first day of rejection treatment for the IgA
CD3 mAbP/CsA group. Small arrows indi-
cate the time points of immunization with teta-
nus toxoid and KLH. (B) Frequencies of IL-4
producing cells within peripheral blood CD4pos
T cells (Y-axis, % of CD4pos T cells) versus time
after entry into the study (X-axis, months). The
symbols are the same as in panel A.
in vitro, gaps remain in our understanding of their mech- of triple immunosuppressive therapy with prednisolone,
cyclosporine A and mycophenolate mofetil. In contrast,anism of action. Here, we studied both cellular and hu-
moral immune responses in renal transplant recipients effector T cell responses are severely reduced: delayed-
type hypersensitivity reactions were hampered, even ifwho were treated with different regimens of immunosup-
pressive drugs, after immunizations to elicit either a pri- the antigen-specific T cells were educated in the absence
of immunosuppression.mary or a secondary immune response in vivo. This study
shows that priming of T cells, specific for new protein In a previous study, no effect of cyclosporine A mo-
notherapy on the in vivo delayed-type hypersensitivityantigens, still occurs in the presence of double immuno-
suppressive drug treatment consisting of prednisolone responses to recall antigens was found [3]. The discrep-
ancy with our data may be explained by the difference inand cyclosporine A, and can even occur in the presence
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pharmacological formulation of cyclosporine A. Neoral protocols, antibody formation directed against equine-
administration is known to result in higher drug level derived polyclonal anti-thymocyte globulin or against
area under the curves as compared to Sandimmune [19]. the murine CD3 monoclonal antibody OKT-3 was sig-
In the above-mentioned study Sandimmune was admin- nificantly impaired in MMF treated patients [24, 25].
istered, as opposed to Neoral, which was used in the This is in contrast to data obtained from previous studies,
present study. Moreover, the addition of 10 mg per day which showed no effect of the combination of predniso-
of prednisolone in our study may have exerted additional lone and azathioprine [20, 26], and a moderate effect on
inhibitory effects on the delayed-type hypersensitivity humoral immune responses in vivo with the addition of
reactions. A similar depressed skin reactivity was found cyclosporine to that combination [27]. Taken together,
in renal transplant recipients treated with prednisone in our results show that addition of MMF to a drug regimen
conjunction with azathioprine [20]. consisting of P/CsA acts directly on the humoral immune
Histological studies on the delayed-type hypersensitiv- response while the T helper cell responses are relatively
ity reaction to KLH indicate an effect of P/CsA treatment spared. These findings imply that vaccination of MMF-
on ICAM-1 expression, leaving the influx of T cells unaf- treated patients, aimed at eliciting an antibody response,
fected. Presumably, ICAM-1 expression is directly inhib- is useless. Next, these findings—at least in part—may
ited by the complex of the glucocorticoid receptor and offer an explanation for the potential of MMF to reduce
prednisolone [21]. In addition, it may be speculated that the occurrence of chronic allograft nephropathy, inde-
tethering of lymphocytes on E-selectin in skin is unaf- pendent of the incidence of acute cellular rejection [11],
fected by this drug regimen. Finally, the severely depressed antibody responses par-
Immunosuppressive treatment with prednisolone and tially may explain the more severe course of CMV infec-
cyclosporine A did not significantly affect the frequen- tion in MMF treated patients.
cies of peripheral blood-derived Th1 or Th2 cells or the
balance between these subsets. Differentiation of naive ACKNOWLEDGMENTS
T cells into Th1 or Th2 cells is mainly driven by the
Drs. Rentenaar and van Diepen are supported by the Dutch Kidneycytokine environment in which naive to memory transi-
Foundation grant number 95-1455. The authors thank the patients for
tion occurs, and is accompanied by switching on specific their participation; Ms. Frederike Bemelman, Ms. Si-La Yong and Ms.
Ingrid Cuales for help with immunizations and blood drawings; Ms.genetic programs while at the same time other genetic
Miriam Coccoris and Ms. Cecilia Sanz Garc¸ia for help with laboratoryprograms are switched off [22]. In vitro, treatment of
experiments; Dr. Theo A. Out and Mr. Richard Reijneke for prepara-
dendritic cells with glucocorticoids impairs their Th1 tion of KLH; Drs. Theo A. Out and Frederiek de Wilde for advice
skewing and enhances their Th2 skewing capacity [5, 6]. on IgG anti-KLH-ELISA; and Mr. Bert Tigges for help with and advice
on immunohistochemical staining procedures.However, upon glucocorticoid treatment in vivo, many
naive to memory transitions of T cells must occur before Reprint requests to Professor R.J.M. ten Berge, M.D., Ph.D., Renal
the peripheral blood Th2 deviation becomes apparent, Transplant Unit F4-215, P.O. Box 22700, 1100 DE Amsterdam, The
Netherlands.thus requiring a more prolonged follow-up of patients.
E-mail: r.j.tenberge@amc.uva.nlAlternatively, co-medication may have inhibited the Th2
skewing effects of prednisolone-treated dendritic cells.
REFERENCESAdministration of a 10 day course of IgA CD3 mono-
1. Rentenaar RJ, Gamadia LE, van der Hoek N, et al: Developmentclonal antibody does not add profound immunosuppres-
of virus-specific CD4() T cells during primary cytomegalovirussive effects on cellular or humoral immune respon-
infection. J Clin Invest 105:541–548, 2000siveness either in vivo or in vitro. In contrast, the addition 2. Gamadia LE, Rentenaar RJ, Baars PA, et al: Differentiation of
of treatment with MMF to P/CsA profoundly decreases cytomegalovirus-specific CD8() T cells in healthy and immuno-
suppressed virus carriers. Blood 98:754–761, 2001both primary and secondary humoral immune respon-
3. van der Heyden AA, Bloemena E, Out TA, et al: The influencesiveness in vivo. In response to KLH, three out of seven of immunosuppressive treatment on immune responsiveness in
patients did not display a T helper cell response, which vivo in kidney transplant recipients. Transplantation 48:44–47, 1989
4. van der Heyden AA, van Oers MH, Cornelissen P, et al: Themay explain in part the absence of the switch to IgG
influence of cyclosporine A treatment on immune responsivenessproduction. However, in response to immunization with
in vitro and in vivo in kidney transplant recipients. Transplant Proc
tetanus toxoid, augmentation of the T helper cell re- 20:190–195, 1988
sponses were detectable in most subjects, whereas four 5. Vieira PL, Kalinski P, Wierenga EA, et al: Glucocorticoids inhibit
bioactive IL-12p70 production by in vitro-generated human den-out of six patients did not respond with increased anti-
dritic cells without affecting their T cell stimulatory potential.gen-specific IgG production. These results are in accor- J Immunol 161:5245–5251, 1998
dance with previously described impairments in antibody 6. de Jong EC, Vieira PL, Kalinski P, Kapsenberg ML: Corticoste-
roids inhibit the production of inflammatory mediators in immatureproduction under MMF treatment. In patients treated
monocyte-derived DC and induce the development of tolerogenicwith P/CsA/MMF, significant impairment of antibody for-
DC3. J Leukoc Biol 66:201–204, 1999
mation to the influenza A virus was observed [23]. In a 7. Brinkmann V, Kristofic C: Regulation by corticosteroids of Th1
and Th2 cytokine production in human CD4 effector T cells gen-comparison among patients with similar drug treatment
Rentenaar et al: Post-transplant immune responsiveness328
erated from CD45RO- and CD45RO subsets. J Immunol 155: membrane: A comparison of semiquantitative and quantitative
analysis. Br J Rheumatol 37:1003–1007, 19983322–3328, 1995
18. Austrup F, Vestweber D, Borges E, et al: P- and E-selectin8. Sollinger HW: Mycophenolate mofetil for the prevention of acute
mediate recruitment of T-helper-1 but not T-helper-2 cells intorejection in primary cadaveric renal allograft recipients. U.S. Renal
inflamed tissues. Nature 385:81–83, 1997Transplant Mycophenolate Mofetil Study Group. Transplantation
19. Barone G, Chang CT, Choc MGJ, et al: The pharmacokinetics60:225–232, 1995
of a microemulsion formulation of cyclosporine in primary renal9. Anonymous: Placebo-controlled study of mycophenolate mofetil
allograft recipients. The Neoral Study Group. Transplantation 61:combined with cyclosporin and corticosteroids for prevention of
875–880, 1996acute rejection: European Mycophenolate Mofetil Cooperative
20. ten Berge RJM, Schellekens PTA, Surachno S, et al: The influ-Study Group. Lancet 345:1321–1325, 1995
ence of therapy with azathioprine and prednisone on the immune10. Anonymous: Mycophenolate mofetil for the treatment of a first
system of kidney transplant recipients. Clin Immunol Immuno-acute renal allograft rejection: Three-year follow-up. The Myco-
pathol 21:20–32, 1981phenolate Mofetil Acute Renal Rejection Study Group. Trans-
21. Liden J, Rafter I, Truss M, et al: Glucocorticoid effects onplantation 71:1091–1097, 2001
NF-kappaB binding in the transcription of the ICAM-1 gene. Bio-11. Ojo AO, Meier-Kriesche HU, Hanson JA, et al: Mycophenolate
chem Biophys Res Commun 273:1008–1014, 2000mofetil reduces late renal allograft loss independent of acute rejec-
22. O’Garra A: Immunology. Commit ye helpers. Nature 404:719–tion. Transplantation 69:2405–2409, 2000
720, 200012. Parlevliet KJ, ten Berge IJM, Yong SL, et al: In vivo effects of
23. Smith KG, Isbel NM, Catton MG, et al: Suppression of the hu-IgA and IgG2a anti-CD3 isotype switch variants. J Clin Invest 93:
moral immune response by mycophenolate mofetil. Nephrol Dial2519–2525, 1994
Transplant 13:160–164, 199813. Korver K, Zeijlemaker WP, Schellekens PT, Vossen JM: Mea-
24. Kimball JA, Pescovitz MD, Book BK, Norman DJ: Reducedsurement of primary in vivo IgM- and IgG-antibody response to human IgG anti-ATGAM antibody formation in renal transplantKLH in humans: Implications of pre-immune IgM binding in anti- recipients receiving mycophenolate mofetil. Transplantation 60:gen-specific ELISA. J Immunol Methods 74:241–251, 1984 1379–1383, 1995
14. Picker LJ, Singh MK, Zdraveski Z, et al: Direct demonstration of 25. Broeders N, Wissing KM, Crusiaux A, et al: Mycophenolate
cytokine synthesis heterogeneity among human memory/effector T mofetil, together with cyclosporin A, prevents anti-OKT3 antibody
cells by flow cytometry. Blood 86:1408–1419, 1995 response in kidney transplant recipients. J Am Soc Nephrol 9:1521–
15. Buysmann S, van Diepen FNJ, Surachno S, et al: Increased dermal 1525, 1998
expression of ICAM-1 and VCAM-1 after administration of OKT3 26. Pabico RC, Douglas RG, Betts RF, et al: Antibody response to
in man. Clin Nephrol 46:84–91, 1996 influenza vaccination in renal transplant patients: Correlation with
16. Tak PP, van der Lubbe P, Cauli A, et al: Reduction of synovial allograft function. Ann Intern Med 85:431–436, 1976
inflammation after anti-CD4 monoclonal antibody treatment in 27 Versluis DJ, Beyer WE, Masurel N, et al: Impairment of the
early rheumatoid arthritis. Arthritis Rheum 38:1457–1465, 1995 immune response to influenza vaccination in renal transplant recip-
17. Youssef PP, Smeets TJ, Bresnihan B, et al: Microscopic measure- ients by cyclosporine, but not azathioprine. Transplantation 42:376-
379, 1986bment of cellular infiltration in the rheumatoid arthritis synovial
